AMPHASTAR PHARMACEUTICALS IN (AMPH)
US03209R1032 - Common Stock
Overall AMPH gets a fundamental rating of 6 out of 10. We evaluated AMPH against 196 industry peers in the Pharmaceuticals industry. AMPH scores excellent on profitability, but there are some minor concerns on its financial health. AMPH may be a bit undervalued, certainly considering the very reasonable score on growth With these ratings, AMPH could be worth investigating further for value investing!.
1. Profitability
1.1 Basic Checks
AMPH had positive earnings in the past year.
AMPH had a positive operating cash flow in the past year.
Each year in the past 5 years AMPH has been profitable.
In the past 5 years AMPH always reported a positive cash flow from operatings.
1.2 Ratios
AMPH's Return On Assets of 9.82% is amongst the best of the industry. AMPH outperforms 92.78% of its industry peers.
AMPH has a Return On Equity of 23.00%. This is amongst the best in the industry. AMPH outperforms 92.27% of its industry peers.
With an excellent Return On Invested Capital value of 12.93%, AMPH belongs to the best of the industry, outperforming 92.27% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for AMPH is significantly below the industry average of 17.97%.
The last Return On Invested Capital (12.93%) for AMPH is above the 3 year average (11.94%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.82% | ||
| ROE | 23% | ||
| ROIC | 12.93% |
ROA(3y)10.22%
ROA(5y)7.84%
ROE(3y)17.58%
ROE(5y)13.18%
ROIC(3y)11.94%
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 22.87%, AMPH belongs to the best of the industry, outperforming 93.81% of the companies in the same industry.
AMPH's Profit Margin has improved in the last couple of years.
AMPH has a better Operating Margin (31.29%) than 94.33% of its industry peers.
AMPH's Operating Margin has improved in the last couple of years.
The Gross Margin of AMPH (54.32%) is better than 63.40% of its industry peers.
AMPH's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31.29% | ||
| PM (TTM) | 22.87% | ||
| GM | 54.32% |
OM growth 3Y114.39%
OM growth 5YN/A
PM growth 3Y276.41%
PM growth 5YN/A
GM growth 3Y10.26%
GM growth 5Y8.62%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so AMPH is still creating some value.
Compared to 1 year ago, AMPH has about the same amount of shares outstanding.
AMPH has more shares outstanding than it did 5 years ago.
The debt/assets ratio for AMPH is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.87 indicates that AMPH is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of AMPH (2.87) is better than 72.68% of its industry peers.
AMPH has a debt to FCF ratio of 3.69. This is a good value and a sign of high solvency as AMPH would need 3.69 years to pay back of all of its debts.
AMPH has a Debt to FCF ratio of 3.69. This is amongst the best in the industry. AMPH outperforms 87.63% of its industry peers.
AMPH has a Debt/Equity ratio of 0.88. This is a neutral value indicating AMPH is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.88, AMPH is doing worse than 69.59% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.88 | ||
| Debt/FCF | 3.69 | ||
| Altman-Z | 2.87 |
ROIC/WACC1.43
WACC9.03%
2.3 Liquidity
AMPH has a Current Ratio of 2.18. This indicates that AMPH is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.18, AMPH is not doing good in the industry: 63.92% of the companies in the same industry are doing better.
AMPH has a Quick Ratio of 1.72. This is a normal value and indicates that AMPH is financially healthy and should not expect problems in meeting its short term obligations.
AMPH's Quick ratio of 1.72 is on the low side compared to the rest of the industry. AMPH is outperformed by 67.01% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.18 | ||
| Quick Ratio | 1.72 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 75.47% over the past year.
Measured over the past years, AMPH shows a very strong growth in Earnings Per Share. The EPS has been growing by 70.36% on average per year.
Looking at the last year, AMPH shows a very strong growth in Revenue. The Revenue has grown by 30.40%.
AMPH shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.94% yearly.
EPS 1Y (TTM)75.47%
EPS 3Y72.76%
EPS 5Y70.36%
EPS Q2Q%67.74%
Revenue 1Y (TTM)30.4%
Revenue growth 3Y22.59%
Revenue growth 5Y16.94%
Sales Q2Q%22.72%
3.2 Future
AMPH is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -4.87% yearly.
Based on estimates for the next years, AMPH will show a small growth in Revenue. The Revenue will grow by 1.16% on average per year.
EPS Next Y17.3%
EPS Next 2Y16.31%
EPS Next 3Y16.21%
EPS Next 5Y-4.87%
Revenue Next Year17.19%
Revenue Next 2Y11.5%
Revenue Next 3Y10.69%
Revenue Next 5Y1.16%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
AMPH is valuated reasonably with a Price/Earnings ratio of 11.42.
Based on the Price/Earnings ratio, AMPH is valued cheaper than 90.72% of the companies in the same industry.
AMPH is valuated cheaply when we compare the Price/Earnings ratio to 24.41, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 9.52, which indicates a very decent valuation of AMPH.
AMPH's Price/Forward Earnings ratio is rather cheap when compared to the industry. AMPH is cheaper than 90.21% of the companies in the same industry.
AMPH is valuated cheaply when we compare the Price/Forward Earnings ratio to 20.59, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.42 | ||
| Fwd PE | 9.52 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of AMPH indicates a rather cheap valuation: AMPH is cheaper than 89.18% of the companies listed in the same industry.
89.18% of the companies in the same industry are more expensive than AMPH, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.91 | ||
| EV/EBITDA | 8.89 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
AMPH has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as AMPH's earnings are expected to grow with 16.21% in the coming years.
PEG (NY)0.66
PEG (5Y)0.16
EPS Next 2Y16.31%
EPS Next 3Y16.21%
5. Dividend
5.1 Amount
AMPH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AMPHASTAR PHARMACEUTICALS IN
NASDAQ:AMPH (7/26/2024, 7:16:20 PM)
After market: 42.48 0 (0%)42.48
+0.34 (+0.81%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.08B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.42 | ||
| Fwd PE | 9.52 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.66
PEG (5Y)0.16
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.82% | ||
| ROE | 23% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 31.29% | ||
| PM (TTM) | 22.87% | ||
| GM | 54.32% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.88 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.18 | ||
| Quick Ratio | 1.72 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)75.47%
EPS 3Y72.76%
EPS 5Y
EPS Q2Q%
EPS Next Y17.3%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)30.4%
Revenue growth 3Y22.59%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y